PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.

  • January 18, 2017
  • Clinical and hemodynamic characteristics of pulmonary hypertension associated with interstitial lung disease in China.
  • (PubMed) Severe hemodynamic impairment along with PH can occur in patients with ILD. These patients have more severely impaired exercise capacity and cardiac function than ILD patients without PH. PVR was the only prognostic factor identified in this group of patients.
  • January 17, 2017
  • Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models
  • (The Phisiological Society) In brief, this proof-of-concept study provides evidence that an M3 muscarinic receptor functionally selective ligand stimulates downstream pathways leading to antihypertensive effects using in vitro, ex vivo, and in vivo models of PH.
  • January 16, 2017
  • Investigating the role of inflammation in pulmonary hypertension: An update
  • (Standford Medicine) The current treatments for pulmonary hypertension focus on dilating pulmonary blood vessels to alleviate pressure in the lungs, Nicolls told me. This treats a symptom of the disease, but not the underlying cause. To address this gap in knowledge, Nicolls; first author Wen Tian, PhD, and his team explored the possible causes of pulmonary hypertension and tested whether a drug, called ubenimex, could effectively treat the source of the disease.
  • January 13, 2017
  • Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension.
  • (PubMed) There is a broad consensus that pulmonary hypertension (PH) is to be diagnosed by right heart catheterization (RHC) and that the most important non-invasive tool is echocardiography. However, the role of simple non-invasive tools in the work-up of PH is not clearly defined. We hypothesized that the use of simple non-invasive techniques may help to guide important decisions in the diagnostics of pulmonary hypertension.
  • January 12, 2017
  • Combo Tx Aids in Scleroderma PAH
  • (MedPage Today) Initial combination therapy with ambrisentan (Letairis) and tadalafil (Cialis) was more effective than monotherapy with either agent alone among patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH), a post-hoc subgroup analysis of the AMBITION trial found.
  • January 11, 2017
  • New apps designed to reduce depression, anxiety as easily as checking your phone
  • (Science Daily) Now you can find help for depression and anxiety on your smartphone as quickly as finding a good sushi restaurant. A novel suite of 13 speedy mini-apps called IntelliCare significantly reduced depression and anxiety in study participants, who used the apps on their smartphones up to four times a day. The reductions of 50 percent in anxiety and depression are comparable to results expected in clinical practice using psychotherapy or with antidepressant medication.
  • January 10, 2017
  •  Pharmacist struck off for supplying counterfeit drugs
  • (Australian Journal of Pharmacy) Mr Mina Attia, the owner of Shopsmart Wholesale pharmacies across Sydney, was brought before the NSW Civil and Administrative Tribunal by the Health Care Complaints Commission (HCCC) following revelations he had introduced counterfeit Viagra into the Sydney pharmaceutical market.
  • First PAH Patient Being Treated with Ubenimex in Extension of Phase 2 Study
  • (Pulmonary Hypertension News) “There has been tremendous enthusiasm in the entire community — patients, families, investigators, and study staff at pulmonary hypertension centers — for the LIBERTY study and a new approach to treating PAH...
  • January 9, 2017
  • She risked her life to give birth. She met the right doctor.
  • (Wisconsin Rapids Trubune)
  • January 6, 2017
  • Stem cells give Stanford scientists a new window into the biology of a rare disease
  • (Stanford Medicine) Today, Stanford pediatric cardiologist Marlene Rabinovitch, MD, and her team published new research that advances their quest to understand a serious — and very puzzling — lung disease. They’re studying pulmonary arterial hypertension,...
  • Statins Show No Benefit When Added to Standard Care for PH Patients
  • (Pulmonary Hypertension News) Statins are usually used to lower cholesterol levels, but they have also been reported to have cholesterol-independent effects that might be helpful to PH patients.
  • January 4, 2017
  • Shortcomings Seen in Way Scleroderma Patients Grouped to Predict Outcomes
  • (Scleroderma News) Current methods of dividing scleroderma patients into groups, based on characteristics of their disease in order to predict its likely progression, gives highly variable results, researchers reported, noting that no single method is able to correctly predict outcomes across groups
  • Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension
  • (ATS Journals) Remodeling of the distal pulmonary artery wall is a characteristic feature of pulmonary hypertension (PH). In hypoxic pulmonary hypertension, the most substantial pathologic changes occur in the adventitia. Here, there is marked fibroblast proliferation and profound macrophage accumulation. These fibroblasts (PH-Fibs) maintain a hyperproliferative, apoptotic resistant and pro-inflammatory phenotype in ex vivo culture. Considering that a similar phenotype is observed in cancer cells, where it has been associated at least in part with specific alterations in mitochondrial metabolism, we sought to define the state of mitochondrial metabolism in PH-Fibs.
  • January 3, 2017
  • Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies
  • (Dove Medical Press) Abstract: Systemic lupus erythematosus (SLE) is characterized by the second highest prevalence of pulmonary arterial hypertension (PAH), after systemic sclerosis, among the connective tissue diseases.
  • January 2, 2017
  • FDA approves selexipag for pulmonary arterial hypertension
  • (The Pharmaceutical Journal) The drug, marketed as Uptravi by Actelion Pharmaceuticals, is an oral prostacyclin receptor (IP) agonist. It is indicated to delay disease progression and reduce the risk of hospital admission for PAH. Selexipag, which has been granted orphan drug designation by the FDA, acts by causing vasodilation, reducing elevated arterial pressure.
  • Patient With Genetic Disease and Pulmonary Hypertension Responds to Treatment Combination
  • (Pulmonary Hypertension News) NF1 is caused by mutations in the genetic coding of the protein neurofibromin. Since the protein helps suppress tumor activity, people with the condition develop tumors in nerves and other parts of the body
  • Iron Deficiency Not Associated with Pulmonary Hypertension, Study Finds
  • (Pulmonary Hypertension News) The researchers defined iron deficiency as blood iron levels lower than 15 ng/mL for women and lower than 30 ng/mL for men. They compared the prevalence of PH in people with iron deficiency and those without
  • December 24, 2016
  • December 23, 2016
  • Arena completes enrollment in trial for oral pulmonary arterial hypertension drug
  • (Cardiovascular Business) The FDA has not approved ralinepag, but it granted the medication an orphan drug designation for pulmonary arterial hypertension in September 2014. An orphan drug designation is intended for medications that treat diseases or conditions affecting fewer than 200,000 individuals in the U.S.
  • December 22, 2016
  • New Treatment Approach for Pulmonary Hypertension May Prove an Effective Option
  • (Pulmonary Hypertension News) The results of the study also showed that when administered together with Letairis (ambrisentan), a drug that is approved for the treatment of PH, TPH1 inhibitors showed an additive effect in reducing lung blood vessel remodeling and pressure.
  • December 21, 2016
  • Predicting Disease Course in PAH Patients Possible with Cardiac Magnetic Resonance, Study Says
  • (Pulmonary Hypertension News) A compilation of results from studies published from 2007–14 confirms that cardiac magnetic resonance (CMR) findings are useful in predicting outcomes in pulmonary arterial hypertension (PAH) patients and, in the future, may help in determining best therapies as the disease progresses.
  • December 20, 2016
  • Capsaicin-induced Ca2+ Signaling is Enhanced via Upregulated TRPV1 Channels in Pulmonary Artery Smooth Muscle Cells from Patients with Idiopathic PAH.
  • (NCBI) Abstract
    Capsaicin is an active component of chili pepper and a pain relief drug. Capsaicin can activate transient receptor potential vanilloid 1 (TRPV1) channels to increase cytosolic Ca2+ concentration ([Ca2+]cyt).

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives